Factors Influencing the Ability of HDL to Inhibit Expression of Vascular Cell Adhesion Molecule-1 in Endothelial Cells

From the University of Adelaide, Department of Medicine, Royal Adelaide Hospital (D.T.A., M.A.C., P.J.B.), the Cardiovascular Investigation Unit, Royal Adelaide Hospital (K.A.-R.), and the Hanson Centre for Cancer Research, Department of Human Immunology, IMVS (M.A.V., J.R.G.), Adelaide, South Australia, Australia.

Correspondence to Professor Philip J. Barter MBBS, PhD, Department of Medicine, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia 5000.

Abstract—We have previously reported that high density lipoproteins (HDLs) inhibit the cytokine-induced expression of adhesion molecules in endothelial cells. Here we investigate whether different preparations of HDLs vary in their ability to inhibit the expression of vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs) activated by tumor necrosis factor- (TNF-). HDLs collected from a number of different human subjects all inhibited VCAM-1 expression in a concentration-dependent manner, although the extent of inhibition varied widely between subjects. The inhibitory activities of the HDL₂ and HDL₃ subfractions isolated from individual subjects also differed. Whether equated for concentrations of apolipoprotein (apo) A-I or cholesterol, the inhibitory activity of HDL₃ was superior to that of HDL₂. This difference remained apparent even when the HDL subfractions were present only during preincubations with the HUVECs and were removed before activation by TNF-. To determine whether the inhibitory effect of HDL₃ was influenced by apolipoprotein composition, preparations of HDL₃ were modified by replacing all of their apo A-I with apo A-II. This change in apolipoprotein composition had no effect on the ability of the HDL₃ to inhibit endothelial VCAM-1 expression. Thus, it has been shown that different preparations of HDLs differ markedly in their abilities to inhibit VCAM-1 expression in cytokine-activated HUVECs. The mechanism underlying the differences remains to be determined.

Key Words: endothelial cells • vascular cell adhesion molecule-1 • HDL • HDL subfractions • atherosclerosis

This article has been cited by other articles:

				M. T Nurmohamed and B. A C Dijkmans Dyslipidaemia, statins and rheumatoid arthritis Ann Rheum Dis, April 1, 2009; 68(4): 453 - 455. [Full Text] [PDF]

				K.-A. Rye, C. A. Bursill, G. Lambert, F. Tabet, and P. J. Barter The metabolism and anti-atherogenic properties of HDL J. Lipid Res., April 1, 2009; 50(Supplement): S195 - S200. [Abstract] [Full Text] [PDF]

				S. Patel, B. G. Drew, S. Nakhla, S. J. Duffy, A. J. Murphy, P. J. Barter, K.-A. Rye, J. Chin-Dusting, A. Hoang, D. Sviridov, et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J. Am. Coll. Cardiol., March 17, 2009; 53(11): 962 - 971. [Abstract] [Full Text] [PDF]

				J. Juarez-Rojas, A. Medina-Urrutia, R Posadas-Sanchez, E Jorge-Galarza, E Mendoza-Perez, N Caracas-Portilla, G Cardoso-Saldana, G Munoz-Gallegos, and C Posadas-Romero High-density lipoproteins are abnormal in young women with uncomplicated systemic lupus erythematosus Lupus, November 1, 2008; 17(11): 981 - 987. [Abstract] [PDF]

				E. M. deGoma, R. L. deGoma, and D. J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211. [Abstract] [Full Text] [PDF]

				S. J. Robins, D. Collins, J. J. Nelson, H. E. Bloomfield, and B. F. Asztalos Cardiovascular Events With Increased Lipoprotein-Associated Phospholipase A2 and Low High-Density Lipoprotein-Cholesterol: The Veterans Affairs HDL Intervention Trial Arterioscler Thromb Vasc Biol, June 1, 2008; 28(6): 1172 - 1178. [Abstract] [Full Text] [PDF]

				G. D. Norata, P. Marchesi, A. Pirillo, P. Uboldi, G. Chiesa, V. Maina, C. Garlanda, A. Mantovani, and A. L. Catapano Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 925 - 931. [Abstract] [Full Text] [PDF]

				M. Moerland, H. Samyn, T. van Gent, M. Jauhiainen, J. Metso, R. van Haperen, F. Grosveld, A. van Tol, and R. de Crom Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice J. Lipid Res., December 1, 2007; 48(12): 2622 - 2631. [Abstract] [Full Text] [PDF]

				A. Kontush, P. Therond, A. Zerrad, M. Couturier, A. Negre-Salvayre, J. A. de Souza, S. Chantepie, and M. J. Chapman Preferential Sphingosine-1-Phosphate Enrichment and Sphingomyelin Depletion Are Key Features of Small Dense HDL3 Particles: Relevance to Antiapoptotic and Antioxidative Activities Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1843 - 1849. [Abstract] [Full Text] [PDF]

				A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]

				S. J. Nicholls, P. Lundman, J. A. Harmer, B. Cutri, K. A. Griffiths, K.-A. Rye, P. J. Barter, and D. S. Celermajer Consumption of Saturated Fat Impairs the Anti-Inflammatory Properties of High-Density Lipoproteins and Endothelial Function J. Am. Coll. Cardiol., August 15, 2006; 48(4): 715 - 720. [Abstract] [Full Text] [PDF]

				P. Kee, D. Caiazza, K.-A. Rye, P.H.R. Barrett, L.A. Morehouse, and P.J. Barter Effect of Inhibiting Cholesteryl Ester Transfer Protein on the Kinetics of High-Density Lipoprotein Cholesteryl Ester Transport in Plasma: In Vivo Studies in Rabbits Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 884 - 890. [Abstract] [Full Text] [PDF]

				G. D. Norata, E. Callegari, M. Marchesi, G. Chiesa, P. Eriksson, and A. L. Catapano High-Density Lipoproteins Induce Transforming Growth Factor-{beta}2 Expression in Endothelial Cells Circulation, May 31, 2005; 111(21): 2805 - 2811. [Abstract] [Full Text] [PDF]

				G. J. de Grooth, A. H. E. M. Klerkx, E. S. G. Stroes, A. F. H. Stalenhoef, J. J. P. Kastelein, and J. A. Kuivenhoven A review of CETP and its relation to atherosclerosis J. Lipid Res., November 1, 2004; 45(11): 1967 - 1974. [Abstract] [Full Text] [PDF]

				P. J. Barter, S. Nicholls, K.-A. Rye, G.M. Anantharamaiah, M. Navab, and A. M. Fogelman Antiinflammatory Properties of HDL Circ. Res., October 15, 2004; 95(8): 764 - 772. [Abstract] [Full Text] [PDF]

				C. Wadham, N. Albanese, J. Roberts, L. Wang, C. J. Bagley, J. R. Gamble, K.-A. Rye, P. J. Barter, M. A. Vadas, and P. Xia High-Density Lipoproteins Neutralize C-Reactive Protein Proinflammatory Activity Circulation, May 4, 2004; 109(17): 2116 - 2122. [Abstract] [Full Text] [PDF]

				A. Kontush, E. C. de Faria, S. Chantepie, and M. J. Chapman Antioxidative Activity of HDL Particle Subspecies Is Impaired in Hyperalphalipoproteinemia: Relevance of Enzymatic and Physicochemical Properties Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 526 - 533. [Abstract] [Full Text]

				A. Kontush, S. Chantepie, and M. J. Chapman Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1881 - 1888. [Abstract] [Full Text] [PDF]

				L. Calabresi, M. Gomaraschi, and G. Franceschini Endothelial Protection by High-Density Lipoproteins: From Bench to Bedside Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1724 - 1731. [Abstract] [Full Text] [PDF]

				S.-i. Miura, M. Fujino, Y. Matsuo, A. Kawamura, H. Tanigawa, H. Nishikawa, and K. Saku High Density Lipoprotein-Induced Angiogenesis Requires the Activation of Ras/MAP Kinase in Human Coronary Artery Endothelial Cells Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 802 - 808. [Abstract] [Full Text] [PDF]

				Z. Ahmed, S. Babaei, G. F. Maguire, D. Draganov, A. Kuksis, B. N. La Du, and P. W. Connelly Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine Cardiovasc Res, January 1, 2003; 57(1): 225 - 231. [Abstract] [Full Text] [PDF]

				G. W. COCKERILL, M. C. MCDONALD, H. MOTA-FILIPE, S. CUZZOCREA, N. E. MILLER, and C. THIEMERMANN High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock FASEB J, September 1, 2001; 15(11): 1941 - 1952. [Abstract] [Full Text] [PDF]

				A. Tedgui and Z. Mallat Anti-Inflammatory Mechanisms in the Vascular Wall Circ. Res., May 11, 2001; 88(9): 877 - 887. [Abstract] [Full Text] [PDF]

				P. W. Baker, K.-A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression J. Lipid Res., August 1, 2000; 41(8): 1261 - 1267. [Abstract] [Full Text]

				A. Kawaguchi, Y. Miyao, T. Noguchi, H. Nonogi, M. Yamagishi, K. Miyatake, Y. Kamikubo, K. Kumeda, M. Tsushima, A. Yamamoto, et al. Intravascular Free Tissue Factor Pathway Inhibitor Is Inversely Correlated With HDL Cholesterol and Postheparin Lipoprotein Lipase but Proportional to Apolipoprotein A-II Arterioscler Thromb Vasc Biol, January 1, 2000; 20(1): 251 - 258. [Abstract] [Full Text] [PDF]

				P. Xia, M. A. Vadas, K.-A. Rye, P. J. Barter, and J. R. Gamble High Density Lipoproteins (HDL) Interrupt the Sphingosine Kinase Signaling Pathway. A POSSIBLE MECHANISM FOR PROTECTION AGAINST ATHEROSCLEROSIS BY HDL J. Biol. Chem., November 12, 1999; 274(46): 33143 - 33147. [Abstract] [Full Text] [PDF]

				P. W. Baker, K.-A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells J. Lipid Res., February 1, 1999; 40(2): 345 - 353. [Abstract] [Full Text]

				D. Sviridov, A. Hoang, W. H. Sawyer, and N. H. Fidge Identification of a Sequence of Apolipoprotein A-I Associated with the Activation of Lecithin:Cholesterol Acyltransferase J. Biol. Chem., June 23, 2000; 275(26): 19707 - 19712. [Abstract] [Full Text] [PDF]